Scholar Rock is a late-stage biopharmaceutical company developing therapies that selectively target growth-factor pathways, especially myostatin. Its lead candidate, apitegromab, is designed to improve muscle function in spinal muscular atrophy and is being expanded into other rare neuromuscular diseases. The company also advances related programs for oncology and fibrotic conditions based on latent TGF-β biology.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -110 | — |
| Q3 2025 | 0 | — | -102.2 | — |
| Q4 2025 | 0 | — | -91 | — |
| Q1 2026 | 0 | — | -105.5 | — |
| Q2 2026 | 0 | — | -109.9 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Duolingo, Inc. (DUOL), Urban Outfitters, Inc. (URBN), The Descartes Systems Group Inc. (DSGX), Pool Corporation (POOL), Bilibili Inc. (BILI), Allegro MicroSystems, Inc. (ALGM)